Bruker
BRKR
$50.30
-21.79%
Bruker Corporation designs and manufactures high-performance scientific instruments and diagnostic solutions for the life sciences, applied markets, pharmaceutical, and biotechnology industries, operating through segments including BSI BioSpin, BSI CALID, BSI Nano, and BEST. As a market leader in advanced analytical tools such as mass spectrometry, NMR, and X-ray diffraction, Bruker differentiates itself through deep technical expertise and a broad portfolio that serves both research and clinical applications. The current investor narrative centers on the company's robust growth acceleration, highlighted by a 63.5% one-year stock price surge, driven by strong demand for its life science tools and a successful expansion into high-growth areas like spatial biology and preclinical imaging. Additionally, the recent launch of innovative products and a strategic focus on operational efficiency have fueled optimism, although the company faces scrutiny over its profitability trajectory and valuation after a period of significant share appreciation.…
BRKR
Bruker
$50.30
Investment Opinion: Should I buy BRKR Today?
Based on the analysis, BRKR is rated a Hold. The stock has strong momentum and a bullish analyst consensus, but the current price is above the average target, and the valuation is stretched. The forward PE of 25.9x implies high expectations for earnings growth, which may not materialize given the modest revenue growth. Investors should wait for a better entry point or evidence of accelerating growth.
Sign up to view all
BRKR 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While the stock has strong momentum and analyst support, the valuation is stretched relative to growth. The key factor is whether revenue growth can accelerate to justify the forward PE. If growth remains below 3%, the stock is likely to underperform; if it accelerates above 5%, there is upside potential. A downgrade to bearish would occur if revenue growth falls below 2% or margins deteriorate, while an upgrade to bullish would require sustained growth acceleration and positive earnings.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bruker's 12-month outlook, with a consensus price target around $59.75 and implied upside of +18.8% versus the current price.
Average Target
$59.75
0 analysts
Implied Upside
+18.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $70
Analyst target range
Bruker is covered by 12 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 2.08 (where 1 is Strong Buy and 5 is Sell). The average price target is $59.75, which is 4.9% below the current price of $62.84, implying a slight downside. The target range is wide, from a low of $40.00 to a high of $70.00, indicating significant uncertainty about the stock's future performance. The high target of $70.00 suggests that some analysts see further upside, likely driven by continued growth in the life sciences tools market and successful product launches, while the low target of $40.00 reflects concerns about valuation and potential margin pressure.
Bulls vs Bears: BRKR Investment Factors
Bruker presents a mixed picture: strong momentum and a bullish analyst consensus are countered by decelerating revenue growth and a premium valuation. The bull case rests on the expectation of a significant earnings recovery, as reflected in the forward PE of 25.9x, while the bear case highlights the modest 2.75% revenue growth and negative net margin. Currently, the bull side has slightly stronger evidence given the stock's momentum and analyst support, but the key tension is whether the company can accelerate growth to justify its valuation. If revenue growth remains subdued, the stock could face a correction toward the average target of $59.75 or lower.
Bullish
- Strong momentum with 63.5% 1-year gain: BRKR has surged 63.5% over the past year, far outpacing the S&P 500's 18.2% gain. The stock is trading near its 52-week high of $65.30, reflecting strong investor confidence and positive market sentiment.
- Forward PE of 25.9x implies earnings recovery: Despite negative trailing EPS, the forward PE of 25.9x suggests the market expects a significant earnings rebound. Analysts estimate EPS of $3.51 for the current fiscal year, indicating a potential turnaround from the recent losses.
- Healthy gross margin of 45.9%: BRKR maintains a robust gross margin of 45.9%, demonstrating pricing power and efficient cost management. This is a key strength for a scientific instruments company, providing a solid foundation for profitability.
- Analyst consensus is Buy: With a mean recommendation score of 2.08 (1=Strong Buy, 5=Sell), analysts are bullish on BRKR. The consensus rating of 'Buy' reflects confidence in the company's growth prospects and product portfolio.
Bearish
- Revenue growth decelerating to 2.75% YoY: Q1 2026 revenue grew only 2.75% YoY to $823.4M, a slowdown from prior quarters. This modest growth may not justify the premium valuation, especially if the trend continues.
- Negative net margin and EPS: BRKR's trailing twelve-month net margin is -0.25%, and EPS is -$0.0012. The company is barely breaking even, and profitability remains a concern despite the strong stock performance.
- Stock trades above average analyst target: The current price of $62.84 is 4.9% above the average analyst target of $59.75, implying limited upside. The low target of $40.00 suggests significant downside risk if sentiment shifts.
- High valuation with PEG of 2.62: The PEG ratio of 2.62 indicates that the stock is expensive relative to its expected earnings growth. This suggests that much of the growth is already priced in, leaving little room for error.
BRKR Technical Analysis
Bruker's stock is in a powerful uptrend, with a 1-year price change of +63.5% and a 3-month change of +70.8%, far outpacing the S&P 500's 3-month gain of 3.7%. The current price of $62.84 sits at 96.2% of its 52-week range (from $28.53 to $65.30), indicating that the stock is trading near its highs, which typically reflects strong momentum but also potential overextension. The 6-month change of +41.9% further underscores the sustained bullish trend, although the recent pullback from the July 30 close of $64.34 to $62.84 suggests some short-term profit-taking.
Beta
1.27
1.27x market volatility
Max Drawdown
-39.9%
Largest decline past year
52-Week Range
$29-$65
Price range past year
Annual Return
+44.9%
Cumulative gain past year
| Period | BRKR Return | S&P 500 |
|---|---|---|
| 1m | -18.4% | +3.6% |
| 3m | +18.9% | +5.1% |
| 6m | +22.6% | +13.8% |
| 1y | +44.9% | +22.2% |
| ytd | +4.6% | +13.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BRKR Fundamental Analysis
Bruker's revenue trajectory shows moderate growth, with the most recent quarter (Q1 2026) reporting revenue of $823.4 million, a 2.75% year-over-year increase. This growth is a slowdown from the prior year's Q1 (which saw revenue of $801.4 million) and reflects a deceleration compared to the 2024-2025 period when quarterly revenue growth was more robust. The company's revenue segments are primarily product-driven, with product revenue of $646.4 million and service/other revenue of $177.0 million, indicating a healthy mix. However, the 2.75% growth rate is modest for a company trading at a premium valuation, and investors are likely watching for acceleration in the coming quarters, especially given the strong stock performance.
Quarterly Revenue
$823400000.0B
2026-03
Revenue YoY Growth
+2.8%
YoY Comparison
Gross Margin
47.3%
Latest Quarter
Free Cash Flow
$51300000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BRKR Overvalued?
Given that Bruker's trailing twelve-month net income is negative (EPS of -$0.0012), the price-to-sales (PS) ratio is the most appropriate valuation metric, and it currently stands at 2.08x, which is below the company's historical average. The forward PE of 25.87x suggests that the market expects a significant earnings recovery, as the trailing PE is not meaningful due to the negative earnings. The gap between the trailing and forward earnings metrics implies that analysts anticipate a substantial improvement in profitability, which is a key driver of the current valuation.
PE
-314.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of 0.83, which could strain cash flows if interest rates rise. The company's negative net margin of -0.25% and negative EPS indicate that profitability is fragile, and any operational misstep could lead to wider losses. Additionally, free cash flow is only $51.3M TTM, which is low relative to the market cap, limiting financial flexibility for investments or dividends.